The rollout would begin the week of Sept. 20 for U.S. residents 18 and older who received their second shot of the Moderna or Pfizer-BioNTech vaccines at least eight months previously.
As pharmaceutical companies declare a need for boosters, scientists and doctors emphasize that there’s no proof yet.
A Pfizer win in a lawsuit against the federal government could cost taxpayers billions of dollars and erase an important control on pharma marketing after decades of regulatory erosion and soaring drug prices, say health policy analysts.
Booster shots are likely to be here before long because of the outdated, 60-year-old basic standard the Food and Drug Administration uses to authorize medicines for sale.
The Centers for Disease Control and Prevention is set to meet on Friday to discuss whether rare instances of a heart disorder merit changing its recommendations for vaccinating teenagers with the Pfizer vaccine.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The FDA just approved the Pfizer vaccine for children ages 12 to 15, setting the stage for the potential vaccination of more than 150,000 more Oregonians.
Pfizer’s management knew last year there was “a mold issue” at the Kansas facility now slated to produce the drugmaker’s urgently needed COVID-19 vaccine.